Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 24195- Ph3 Double blind Adagrasib+Pembro+Chemo vs Placebo+Pembro+Chemo Untreated NSCLC (KRYSTAL-4)
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4)
Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Chicago, Niles